SECsense Logo

Novavax, Inc. 8-K Report: Key Updates on Corporate Changes (Dec 12, 2024)

$NVAX
Form 8-K
Filed on: 2024-12-18
Source
Novavax, Inc. 8-K Report: Key Updates on Corporate Changes (Dec 12, 2024)

Based on the provided section of the financial report, here are the key elements extracted:

  1. Entity Information:
  • Company Name: Novavax, Inc.
  • CIK (Central Index Key): 0001000694
  • SEC File Number: 0-26770
  • EIN (Employer Identification Number): 22-2816046
  • Address: 700 Quince Orchard Road, Gaithersburg, MD 20878
  • Contact Number: 240-268-2000
  1. Filing Details:
  • Filing Type: 8-K (a report of unscheduled material events or corporate changes)
  • Filing Date: December 12, 2024
  1. Stock Information:
  • Common Stock:
    • Par Value: $0.01 per share
    • Ticker Symbol: NVAX
    • Exchange: NASDAQ
  1. Context:
  • Reporting Date: December 12, 2024
  • Unit of Measurement:
    • Currency: USD (United States Dollar)
    • Shares: Indicates that share count or values may be included in the report.
  1. Schema Reference:
  • The document references a schema file (nvax-20241212.xsd), which may provide further structure or validation rules for the data presented in the filing.

Insights:

  • The filing is an 8-K, which indicates that Novavax might be reporting significant events that investors should be aware of, such as changes in management, new contracts, or other major developments.
  • The document focuses on common stock, which could suggest potential updates related to equity financing, stock performance, or corporate governance.
  • The reporting date aligns with the filing date, indicating that information is current as of December 12, 2024, which is essential for understanding the timeliness of the report.
  • The presence of a specific schema reference suggests that the data is structured for compliance and ease of analysis, which is common in SEC filings.

This analysis indicates that stakeholders should review the details of the 8-K filing for any critical events that could impact Novavax's stock performance or business operations.